Biotechnology company Nanoscope Therapeutics recently announced the formation of Vision Advisory Committee (VAC). 1 VAC is “a group of renowned experts in retina treatment and commercialization,” a ...

Christine Kay, MD, presented interim 1-year data from a phase 1/2 study of an investigational gene therapy (OPGx-LCA5; Opus Genetics) for LCA5-related Leber congenital amaurosis at the Clinical Trials ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Ahead of the Clinical Trials at the Summit (CTS) meeting in Las Vegas, Nevada, Victor Gonzalez, MD, shared an overview of his presentation. Dr. Gonzalez is a trial investigator in the REMAIN follow-up ...

An Indonesian study of the characteristics of the retinal vasculature found that the retinal vessel tortuosity (VT) was significantly higher and the fractal dimension (FD) was significantly lower in ...

Researchers with the National Institutes of Health (NIH) has identified in a recent study which brain circuits are essential for visual acuity and how they may be affected by retinal cell damage. The ...

In a comprehensive study of geographic atrophy (GA) treatment, Deepak Sambhara, MD, from the Eye Clinic of Wisconsin analyzed long-term patient compliance with two recently FDA-approved complement ...

Biotechnology company Lineage Cell Therapeutics recently announced it will be presenting data from its phase 1/2a clinical study (NCT02286089) at the upcoming Clinical Trials at the Summit (CTS) 2025 ...

Ashvattha Therapeutics recently announced positive interim phase 2 results for migaldendranib (MGB). 1 MGB is described as a novel subcutaneously administered nanomedicine for the treatment of retinal ...

Matt Star, MD, assistant professor of ophthalmology and the Program Director of the residence program at the Mayo Clinic, discusses the RHONE-X trial. RHONE-X is a long-term, multicentered, open-label ...

Alkeus Pharmaceuticals, Inc., announced additional data from its Phase 2 clinical SAGA study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In this trial patients ...